Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2252 in Advanced Malignant Tumors
NCT06649656Phase 1Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2223 + penpulimab in advanced malignant solid tumor and lymphoma, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Adverse events rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
TQB2223 + penpulimab
03
Conditions
advanced malignant solid tumorlymphoma
Beyond the preview
Go deeper on NCT06649656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649656.